In this context, the absolute risk reductions afforded by GLP-1 RA therapy become more pronounced, as demonstrated in multiple cardiovascular outcome trials where the benefits were most evident among those with prior disease 4,10,41
Retatrutide is an investigational compound not approved for any therapeutic use
The good news: Yes, thats likely
"GLP-1 Patient Access Report Q3/Q4 2025." Mass.gov
Within five weeks I dropped another 11 pounds and my energy feels higher than before
Diana Girnita, MD, PhD , is a double board-certified rheumatologist and internal medicine specialist with over 20 years of clinical and research experience